KL-11743

• CAT Number: I045095
• CAS Number: 1369452-53-8
• Molecular Formula: C30H30N6O3
• Molecular Weight: 522.60
• Purity: ≥95%
• Synonyms: 2-[3-[6-ethoxy-4-[4-(1H-pyrazol-4-yl)anilino]quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide
• InChI: InChI=1S/C30H30N6O3/c1-4-38-25-12-13-27-26(15-25)30(34-23-10-8-20(9-11-23)22-16-31-32-17-22)36-29(35-27)21-6-5-7-24(14-21)39-18-28(37)33-19(2)3/h5-17,19H,4,18H2,1-3H3,(H,31,32)(H,33,37)(H,34,35,36)
• InChIKey: XKOYTLRGOQTKAU-UHFFFAOYSA-N
• SMILES: CCOC1=CC2=C(C=C1)N=C(N=C2NC3=CC=C(C=C3)C4=CNN=C4)C5=CC(=CC=C5)OCC(=O)NC(C)C

KL-11743（Cat No.:I045095）is an investigational small-molecule inhibitor targeting maternal embryonic leucine zipper kinase (MELK), a serine/threonine kinase implicated in cancer cell proliferation, stemness, and resistance to therapy. By selectively inhibiting MELK, KL-11743 disrupts cell cycle progression and induces apoptosis in tumor cells, particularly in aggressive cancers such as glioblastoma, triple-negative breast cancer, and hematologic malignancies. It holds promise for overcoming treatment resistance and targeting cancer stem cells. KL-11743 is currently under preclinical evaluation and is supplied for research focused on kinase inhibition, tumor biology, and novel anti-cancer strategies.